FHTX News and Press, Foghorn Therapeutics Inc.

2026-03-12 18:15:03 ET Jefferies analyst issues BUY recommendation for FHTX on March 12, 2026 08:44PM ET. The previous analyst recommendation was Buy. FHTX was trading at $4.92 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analy...

EHang Holdings Limited (EH) is expected to report $-0.06 for Q4 2025 McEwen Inc. (MUX) is expected to report $0.25 for Q4 2025 Hannover Ruck SE ADR - Level I (HVRRY) is expected to report $1.03 for Q4 2025 VAALCO Energy Inc. (EGY) is expected to report $0.02 for Q4 2025 Full Truck...

2026-03-11 16:38:07 ET More on Foghorn Therapeutics Seeking Alpha’s Quant Rating on Foghorn Therapeutics Historical earnings data for Foghorn Therapeutics Financial information for Foghorn Therapeutics Read the full article on Seeking Alpha For...

FHD-909 (LY4050784) Phase 1 dose-escalation advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-small cell lung cancer (NSCLC) Selective CBP degrader program with potential in ER+ breast cancer tracking to IND-enabling studies in 2026 Selective EP300 degrader...

Transportadora de Gas del Sur SA TGS (TGS) is expected to report $0.51 for Q4 2025 John Wiley & Sons Inc. (WLY) is expected to report $0.86 for Q3 2026 Foghorn Therapeutics Inc. (FHTX) is expected to report $-0.28 for Q4 2025 Costco Wholesale Corporation (COST) is expected to repo...

2026-02-23 07:27:07 ET More on Foghorn Therapeutics Seeking Alpha’s Quant Rating on Foghorn Therapeutics Historical earnings data for Foghorn Therapeutics Financial information for Foghorn Therapeutics Read the full article on Seeking Alpha For...

WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that Ryan Maynard will join the compan...

2026-02-13 14:01:58 ET More on pharmaceuticals, biotech Big Pharma's Earnings Week: Strong Performance, Obesity Wars, LOE Management And More BBH: Mature Biotech Exposure, But Limited Growth Ahead XPH: Healthcare Dashboard For January Most and least shorted m...

WATERTOWN, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in th...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – The global oncology market is charging toward a massive $668 billion valuation by 2034 [1] , fueled by a structural shift where institutional capital is abandoning discovery-stage...